NEW YORK, May 20, 2026
Pfizer announced strong positive Phase 2 clinical trial results for its investigational 25-valent pneumococcal conjugate vaccine candidate (25vPnC), supporting the company’s decision to advance the pediatric vaccine program into pivotal Phase 3 development. The findings, presented during the International Society of Pneumonia & Pneumococcal Diseases (ISPPD) 2026 meeting in Copenhagen, demonstrated robust immunogenicity, expanded serotype coverage, and a favorable safety profile in infants. Pfizer stated that the next-generation vaccine candidate could potentially provide protection against up to 90% of pneumococcal disease-causing serotypes in children under five years of age, including improved protection against the highly problematic serotype 3.
The Phase 2 study evaluated a four-dose vaccination schedule administered at 2, 4, 6, and 12–15 months of age, comparing Pfizer’s investigational 25vPnC vaccine candidate with the currently approved PREVNAR 20® vaccine. Researchers reported significantly stronger immune responses for multiple serotypes, particularly serotype 3, which continues to remain one of the major causes of invasive pneumococcal disease and complicated pneumonia in pediatric populations despite existing vaccination programs.
Strong Serotype 3 Response Supports Next-Generation Vaccine Strategy
According to the clinical data presented at ISPPD 2026, infants receiving Pfizer’s 25vPnC vaccine generated approximately 8.8-fold higher geometric mean antibody titers against serotype 3 after Dose 3 compared with PREVNAR 20. Following Dose 4, the immune response increased further, showing approximately 15-fold higher serotype 3 immunogenicity versus the standard-of-care vaccine. Researchers highlighted that improving protection against serotype 3 remains a critical objective because the strain continues to contribute significantly to severe pneumococcal infections in children worldwide.
Pfizer’s investigational vaccine expands protection beyond the 20 serotypes currently included in PREVNAR 20 by adding five additional serotypes: 15A, 23A, 23B, 24F, and 35B. Company officials stated that these newly included serotypes could provide approximately 25% broader invasive pneumococcal disease coverage compared with existing vaccines. The company believes this expanded coverage could significantly reduce residual pediatric pneumococcal disease burden globally.
Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer at Pfizer, stated that although pneumococcal vaccines have transformed pediatric infectious disease prevention over the past two decades, substantial disease burden still exists. She emphasized that the Phase 2 data strengthens Pfizer’s confidence in delivering broader and more durable protection against emerging pneumococcal serotypes through next-generation vaccine technology.
Advertisement
Phase 3 Pediatric Program Officially Initiated
Following discussions with regulatory authorities and evaluation of the positive Phase 2 results, Pfizer confirmed that it officially initiated its pivotal pediatric Phase 3 program in May 2026. The global Phase 3 studies will evaluate the safety, tolerability, and immunogenicity of the 25vPnC vaccine candidate in approximately 2,400 healthy children receiving four-dose vaccination schedules. Participants will receive either Pfizer’s investigational vaccine or the currently licensed 20-valent comparator vaccine throughout the study period.
The company noted that the safety and tolerability profile observed during Phase 2 was consistent with currently approved pneumococcal vaccines. The most common adverse reactions included injection site redness, swelling, pain, irritability, fever, decreased appetite, and drowsiness, with no major safety concerns identified. Researchers stated that overall reactogenicity remained comparable to existing pediatric pneumococcal vaccines currently used in routine immunization programs.
Pfizer Expands Long-Term Pneumococcal Vaccine Leadership
In addition to advancing the pediatric program, Pfizer also announced plans to strengthen its long-term leadership in the adult pneumococcal vaccine market by moving directly into development of a fifth-generation 35-valent adult vaccine candidate. The investigational adult vaccine aims to further increase serotype coverage while also improving immune responses against clinically important strains such as serotype 3 using Pfizer’s proprietary next-generation vaccine technology platform.
Pfizer expects the 35-valent adult vaccine candidate to enter clinical development by the end of 2026 pending regulatory alignment. Industry analysts believe the company’s aggressive next-generation pneumococcal vaccine strategy reflects increasing competition in the global vaccine market, where broader serotype coverage and stronger immune durability are becoming major differentiators among manufacturers.
Pneumococcal disease remains a major global public health challenge, particularly among infants, older adults, and immunocompromised populations. The disease can lead to severe infections such as pneumonia, meningitis, bloodstream infections, and middle ear infections. Healthcare experts believe expanded vaccine coverage against emerging serotypes could play a critical role in further reducing hospitalization and mortality rates worldwide.
Source: Pfizer press release
